Highlight
Efficacy Hierarchies Confirmed
Clozapine, amisulpride, olanzapine, and risperidone were found to be more efficacious than at least three other antipsychotics, with all studied drugs outperforming placebo in reducing acute symptoms of schizophrenia.
The Rise of Muscarinic Agents
Xanomeline-trospium, a first-in-class muscarinic receptor agonist, demonstrates significant efficacy without the traditional adverse effects associated with dopamine-blocking agents, though it introduces a distinct set of cholinergic and anticholinergic side effects.
Methodological Rigor and Global Reach
This study represents one of the most comprehensive syntheses to date, incorporating 438 randomized controlled trials (RCTs) from international and Chinese databases, involving 78,193 participants to ensure high statistical power.
Clinical Guideline Implications
The finding of small-to-medium clinically relevant differences between antipsychotics suggests that clinical guidelines should place a stronger emphasis on individualized drug selection based on specific efficacy and tolerability profiles.
Background: The Evolution of Schizophrenia Pharmacotherapy
For over seven decades, the pharmacological management of schizophrenia has been dominated by the dopamine hypothesis. Since the discovery of chlorpromazine, the primary mechanism of action for virtually all licensed antipsychotics has centered on the blockade of dopamine D2 receptors. While effective in mitigating positive symptoms such as hallucinations and delusions, these antidopaminergic agents carry a heavy burden of side effects, including extrapyramidal symptoms (EPS), hyperprolactinemia, and metabolic syndrome.
In 2024, the therapeutic landscape shifted significantly with the licensing of xanomeline-trospium. This novel agent acts as a muscarinic receptor agonist, targeting M1 and M4 receptors to modulate neurotransmission upstream of the dopamine system. By avoiding direct D2 receptor blockade, muscarinic agents offer hope for a reduced burden of motor and endocrine side effects. However, the relative standing of this new class compared to established antidopaminergic agents—both first- and second-generation—required a rigorous, comparative evaluation. This study, published in The Lancet, provides that essential evidence through a comprehensive network meta-analysis (NMA).
Study Design: A Global Evidence Synthesis
The researchers conducted a systematic review and network meta-analysis (PROSPERO, CRD42022380708) including blinded and open RCTs. The target population included participants of any age experiencing acute psychotic symptoms of schizophrenia, with study durations ranging from 3 weeks to 3 months.
The intervention arm included 23 primarily dopamine-receptor blocking medications and xanomeline-trospium in various applications. A distinctive feature of this study was its extensive search of five Chinese databases alongside the Cochrane Schizophrenia Group’s register and previous reviews. The search spanned from database inception to July 26, 2024.
Methodological quality was strictly controlled. After identifying 5,117 Chinese trials, the majority were excluded due to a lack of author response or serious methodological concerns regarding randomization. Ultimately, the NMA included 438 RCTs, with 388 providing usable data for at least one outcome. The primary endpoint was the reduction in overall symptoms of schizophrenia measured by standardized rating scales (e.g., PANSS or BPRS). Secondary outcomes encompassed 32 additional efficacy and tolerability metrics, with confidence in estimates assessed via the CINeMA (Confidence in Network Meta-Analysis) approach.
Key Findings: Efficacy and the Performance of Xanomeline-Trospium
Primary Efficacy Outcomes
The analysis confirmed that all 24 evaluated antipsychotics were significantly more effective than placebo. The standardized mean differences (SMD) for symptom reduction ranged from -0.90 (95% CI -1.03 to -0.77) at the high end to -0.23 (95% CI -0.39 to -0.06) at the lower end.
Four medications stood out for their superior efficacy. Clozapine, amisulpride, olanzapine, and risperidone were found to be more efficacious than at least three other antipsychotics. Although clozapine remains the gold standard for treatment-resistant schizophrenia, its use in acute settings is often limited by its safety profile. Amisulpride and olanzapine also demonstrated robust symptom reduction, though the confidence in these estimates was categorized as low-to-moderate.
The Performance of Xanomeline-Trospium
Xanomeline-trospium demonstrated clear efficacy over placebo, marking it as a viable alternative to dopamine-blocking agents. While it did not surpass the most efficacious traditional agents (like clozapine or amisulpride) in head-to-head network comparisons for overall symptom reduction, its primary value lies in its unique mechanism. It provides a therapeutic option for patients who are either non-responsive to or unable to tolerate D2-blocking agents.
Tolerability: The Deciding Factor in Clinical Choice
While efficacy differences were noted, the most striking variations occurred in the realm of adverse effects. The study highlighted that the choice of antipsychotic must be highly individualized based on the patient’s risk profile for specific side effects.
Dopaminergic vs. Muscarinic Adverse Effects
Traditional antidopaminergic agents were associated with expected side effects: EPS (haloperidol, risperidone), weight gain (olanzapine, clozapine, quetiapine), and prolactin elevation (paliperidone, risperidone). In contrast, xanomeline-trospium lacked these dopamine-mediated adverse events. However, it was not free of side effects; instead, it presented a cholinergic/anticholinergic profile, including nausea, vomiting, and constipation. The addition of trospium—a peripheral muscarinic antagonist—is designed to mitigate these peripheral effects, but they remain a consideration for clinical management.
Partial Agonists and General Tolerability
Partial dopamine agonists (such as aripiprazole, brexpiprazole, and cariprazine) were found to have an overall better tolerability profile regarding metabolic and motor side effects compared to full D2 antagonists, reinforcing their role in long-term maintenance and for patients sensitive to weight gain or sedation.
Expert Commentary: Interpreting the Data for Practice
This NMA underscores a critical reality in psychiatry: antipsychotics are not interchangeable. The small-to-medium clinically relevant differences in efficacy observed between drugs like clozapine and lower-potency agents should be more explicitly addressed in clinical guidelines.
One significant limitation noted by the authors is the quality of available data. The exclusion of thousands of trials—particularly from Chinese databases—due to methodological concerns highlights the ongoing need for high-quality, transparently reported RCTs in global psychiatry. Furthermore, while xanomeline-trospium is a promising addition, the authors emphasize that future research must include direct head-to-head comparisons between muscarinic agonists and established antipsychotics to confirm its place in the treatment hierarchy.
There is also a pressing need for modern trials investigating the early use of clozapine. Historically reserved for treatment-resistant cases, earlier intervention with clozapine might potentially improve long-term outcomes and prevent the chronification of schizophrenia, though this remains to be proven in contemporary cohorts.
Conclusion: Moving Toward Individualized Schizophrenia Care
The results of this network meta-analysis provide a roadmap for clinicians managing acute schizophrenia. While traditional agents like clozapine and olanzapine remain highly effective, the introduction of xanomeline-trospium expands the toolkit, offering a non-dopaminergic pathway for symptom control. The choice of medication should remain a shared decision-making process, balancing the superior efficacy of certain agents against the specific side-effect vulnerabilities of the individual patient.
Funding and ClinicalTrials.gov
This study was funded by the German Research Foundation (DFG), the German Ministry of Research, Technology and Space, and the National Natural Science Foundation of China. The systematic review protocol is registered with PROSPERO (CRD42022380708).
References
1. Schneider-Thoma J, Zhu Y, Qin M, et al. Comparative efficacy and tolerability of antidopaminergic and muscarinic antipsychotics for acute schizophrenia: a network meta-analysis of randomised controlled trials indexed in international English and Chinese databases. Lancet. 2026 Feb 28;407(10531):876-891. doi: 10.1016/S0140-6736(25)02365-7.
2. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951-962.
3. Kaul I, Sawchak S, Correll CU, et al. Efficacy and safety of xanomeline and trospium chloride in schizophrenia: a randomized phase 3 trial (EMERGENT-2). Lancet. 2024;403(10422):160-170.
